Branches of biology

Virios Therapeutics, Inc. Interview to Air on Bloomberg Television U.S. on the RedChip Money Report

Friday, April 16, 2021 - 12:05pm

These trial results are suggestive that IMC-1 may represent a new and novel treatment for fibromyalgia.

Key Points: 
  • These trial results are suggestive that IMC-1 may represent a new and novel treatment for fibromyalgia.
  • The company is led by an executive team highly experienced in the successful development and commercialization of novel therapies.
  • Forward-looking statements are based on Virios Therapeutics\xe2\x80\x99 current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict.
  • Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate.

Precision BioSciences Reacquires Global Rights to its Allogeneic CAR T Programs

Thursday, April 15, 2021 - 9:10pm

This includes its two clinical stage CD19-targeting allogeneic CAR T candidates, PBCAR0191 and PBCAR19B stealth cell, as well as four additional product targets.\n\xe2\x80\x9cWe are excited about the potential of our allogeneic CAR T pipeline to deliver off-the-shelf treatments for patients with cancer,\xe2\x80\x9d said Matt Kane, CEO and Co-Founder of Precision BioSciences.

Key Points: 
  • This includes its two clinical stage CD19-targeting allogeneic CAR T candidates, PBCAR0191 and PBCAR19B stealth cell, as well as four additional product targets.\n\xe2\x80\x9cWe are excited about the potential of our allogeneic CAR T pipeline to deliver off-the-shelf treatments for patients with cancer,\xe2\x80\x9d said Matt Kane, CEO and Co-Founder of Precision BioSciences.
  • \xe2\x80\x9cWe believe we are in a unique position with multiple near-term opportunities to achieve success with allogeneic CAR T cells targeting CD19.
  • PBCAR19B is designed to improve the persistence of allogeneic CAR T cells following infusion by reducing rejection by T cells and NK cells.
  • Reducing or knocking-down Class I MHC expression on allogeneic CAR T cells has been shown to reduce CAR T cell killing by cytotoxic T cells.

Focal Segmental Glomerulosclerosis (FSGS) Pipeline Insight Report 2020: Comprehensive Insights About 15+ Companies and 15+ Pipeline Drugs - ResearchAndMarkets.com

Thursday, April 15, 2021 - 5:52pm

b'This segment of the Focal Segmental Glomerulosclerosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.

Key Points: 
  • b'This segment of the Focal Segmental Glomerulosclerosis report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery.
  • Retrophin is examining the ability of sparsentan to slow the decline of kidney function in patients with FSGS and IgAN.
  • It is a single molecule designed to be a dual endothelin receptor type A (ETA) and angiotensin II receptor type 1 (AT1) antagonist.
  • It is currently in phase II stage of development.\nDelta 4 is working on its lead program which aims at developing a therapy for Focal Segmental Glomerulosclerosis (FSGS).

2021 Pipeline Insights into Collagen Inhibitors - Featuring Shanghai Genomics, Matrizyme & Roche Among Others - ResearchAndMarkets.com

Thursday, April 15, 2021 - 5:11pm

b'The "Collagen Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\nThis report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Collagen inhibitors pipeline landscape.

Key Points: 
  • b'The "Collagen Inhibitors - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com\'s offering.\nThis report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Collagen inhibitors pipeline landscape.
  • It further highlights the inactive pipeline products in this space.\nCollagen is an essential part of the framework of the design of our various body tissues.
  • Unlike canonical inhibitors of excessive accumulation of collagen-rich deposits, inhibition of collagen fibril formation targets a specific, extracellular event.
  • phase 2 include, miRagen Therapeutics.\nCollagen inhibitors pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Cluster Headache Epidemiology Insight Report 2021-2030 - ResearchAndMarkets.com

Thursday, April 15, 2021 - 1:22pm

b'The "Cluster Headache - Epidemiology Insight - 2030" report has been added to ResearchAndMarkets.com\'s offering.\nThis \'Cluster Headache (CH) - Epidemiology Forecast - 2030\' report delivers an in-depth understanding of and historical and forecasted epidemiology of Cluster Headache in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.\nThe CH epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries.

Key Points: 
  • b'The "Cluster Headache - Epidemiology Insight - 2030" report has been added to ResearchAndMarkets.com\'s offering.\nThis \'Cluster Headache (CH) - Epidemiology Forecast - 2030\' report delivers an in-depth understanding of and historical and forecasted epidemiology of Cluster Headache in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.\nThe CH epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries.
  • It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders.
  • This part of the report also provides the diagnosed patient pool and their trends and assumptions undertaken.\nThe epidemiology segment also provides the Cluster Headache epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.\nThe total prevalent cases of Cluster Headache associated in 7MM countries were 877,859 in 2020.\nAs per the estimates, the United States has the largest prevalent population of Cluster Headache.\nAmong the EU5 countries, Germany had the highest prevalent cases of Cluster Headache, followed by France.
  • On the other hand, Spain had the lowest prevalent cases, with 61,798 cases in 2020.\n'

Worldwide Topical Pain Relief Industry to 2025 - by Therapeutic Class, Mode of Purchase and Region - ResearchAndMarkets.com

Thursday, April 15, 2021 - 1:15pm

b'Analyses of the global market trends, with data from 2019 and 2020, and projections of compound annual growth rates (CAGRs) through 2025\nExamination of the competitive environment, regulatory scenario and technological advancements which are influencing the growth of generic drugs market\nProfiles of the leading market players, including GlaxoSmithKline, Sanofi S.A., Johnson & Johnson, Sun Pharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Ltd.\nGrowth of the global market is attributed to factors such as the growing prevalence of cancer, diabetes and other chronic diseases; and strong investment in research and development activities by key market players including GlaxoSmithKline, SanofiS.A., Johnson& Johnson, SunPharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Ltd., among others.\nThe increasing incidence of acute and chronic pain and rising geriatric populations with osteoporosis-related issues are the major factors likely to fuel the market for topical pain management drugs.\nAccording to the Global Burden of Disease Study 2016, the high prominence of pain and pain-related diseases is the leading cause of disability and disease burden globally.

Key Points: 
  • b'Analyses of the global market trends, with data from 2019 and 2020, and projections of compound annual growth rates (CAGRs) through 2025\nExamination of the competitive environment, regulatory scenario and technological advancements which are influencing the growth of generic drugs market\nProfiles of the leading market players, including GlaxoSmithKline, Sanofi S.A., Johnson & Johnson, Sun Pharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Ltd.\nGrowth of the global market is attributed to factors such as the growing prevalence of cancer, diabetes and other chronic diseases; and strong investment in research and development activities by key market players including GlaxoSmithKline, SanofiS.A., Johnson& Johnson, SunPharmaceutical Industries Ltd. and Teva Pharmaceutical Industries Ltd., among others.\nThe increasing incidence of acute and chronic pain and rising geriatric populations with osteoporosis-related issues are the major factors likely to fuel the market for topical pain management drugs.\nAccording to the Global Burden of Disease Study 2016, the high prominence of pain and pain-related diseases is the leading cause of disability and disease burden globally.
  • In 2016, the burden of chronic pain increased, with 1.9 billion people with symptomatic chronic conditions.
  • The burden of chronic pain is likely to drive the market for topical pain management drugs during the forecast period.\nThe global topical pain management drugs market is segmented based on therapeutic class, mode of purchase and region.\n'

Global Pain Therapeutics Market Report 2021 - Profiling 173 Companies Along with 156 Collaborators - ResearchAndMarkets.com

Thursday, April 15, 2021 - 12:46pm

b'The "Pain Therapeutics - Drugs, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com\'s offering.\nThis report describes the latest concepts of pathomechanisms of pain as a basis for the management and development of new pharmacotherapies for pain.

Key Points: 
  • b'The "Pain Therapeutics - Drugs, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com\'s offering.\nThis report describes the latest concepts of pathomechanisms of pain as a basis for the management and development of new pharmacotherapies for pain.
  • Major segments of the pain market are arthritis, neuropathic pain and cancer pain.
  • Management of pain is multidisciplinary and includes both pharmacological and non-pharmacological methods such as acupuncture, transcutaneous electrical nerve stimulation and surgery.
  • The report is supplemented with 77 tables, 25 figures, and 600 selected references to the literature.\nThe report contains information on the following:\n'

Global Regenerative Medicines Market 2020-2030: Opportunities in Drug Approvals and Strong Pipeline of Cell and Gene Therapies & Multiple Investments in Expansion of cGMP Units - ResearchAndMarkets.com

Thursday, April 15, 2021 - 12:07pm

Cell and gene therapies, though advancing at a rapid pace, have primarily been targeted for hematological malignancies.\nHowever, the same potential has not been replicated in solid tumor applications, consequently creating demand for cell therapies focusing on solid tumors.

Key Points: 
  • Cell and gene therapies, though advancing at a rapid pace, have primarily been targeted for hematological malignancies.\nHowever, the same potential has not been replicated in solid tumor applications, consequently creating demand for cell therapies focusing on solid tumors.
  • Such trends are consistently propelling the industry toward realizing the true potential of precision medicine.\nWithin the research report, the market is segmented on the basis of products, applications, and region.
  • Major manufacturers of regenerative medicine products are actively involved in undertaking significant business strategies in order to translate success in research and development into the commercial clinical setting.
  • Although tissue engineering and stem cells remain the dominating product segments, the advent of cell and gene therapy has revolutionized the regenerative medicine phenomenon, moving it more toward the precision medicine space.\n'

$1.13 Bn Marine Collagen Markets, 2026 by Type (Type I, Type III), Application (Nutraceuticals, Cosmetic, Medical), Source (Skin, Scales, and Muscles, Bones & Tendons) - ResearchAndMarkets.com

Thursday, April 15, 2021 - 10:34am

b'The "Marine Collagen Market by Type (Type I, Type III), Application (Nutraceuticals, Cosmetic, Medical), Source (Skin, Scales, and Muscles, Bones & Tendons), Animal and Region - Trends and Global Forecast to 2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe global marine collagen market size is estimated to be valued at USD 778 million in 2021 and projected to reach USD 1,137 million by 2026, recording a CAGR of 7.9% during the forecast period.\nThe increasing disposable income among consumers and rising awareness regarding beauty and personal care segments is expected to contribute to the growth of the marine collagen market.\nBy type, type I marine collagen segment is projected to dominate the market during the forecast period.\nThe type I marine collagen segment is projected to account for the largest share by type in the marine collagen market.

Key Points: 
  • b'The "Marine Collagen Market by Type (Type I, Type III), Application (Nutraceuticals, Cosmetic, Medical), Source (Skin, Scales, and Muscles, Bones & Tendons), Animal and Region - Trends and Global Forecast to 2026" report has been added to ResearchAndMarkets.com\'s offering.\nThe global marine collagen market size is estimated to be valued at USD 778 million in 2021 and projected to reach USD 1,137 million by 2026, recording a CAGR of 7.9% during the forecast period.\nThe increasing disposable income among consumers and rising awareness regarding beauty and personal care segments is expected to contribute to the growth of the marine collagen market.\nBy type, type I marine collagen segment is projected to dominate the market during the forecast period.\nThe type I marine collagen segment is projected to account for the largest share by type in the marine collagen market.
  • This is attributed to the rise in consumption and preference among consumers due to the intrinsic health benefits of type I marine collagen and its effectiveness as a protein source.\nType I marine collagen offers exemplary health benefits such as joint treatment, bone growth promotion, and maintenance of hair, nails and teeth.
  • This can be attributed to the rise in the millennial population with sufficient disposable income to afford the purchase of nutraceutical and beauty supplements.\nIn addition, developing countries like China, India and Japan are witnessing a major preference for personal care and beauty products, which has led to a rise in the demand for marine collagen.
  • Surging internet penetration regarding the ongoing health and wellness trend among the millennial population is also a driving factor for the marine collagen market.\nLeading players profiled in this report include the following:\n'

ROSALIND, HELiXrUS and Geninus Partner to Bring Powerful New Single Cell Analysis Services to Cancer Researchers

Thursday, April 15, 2021 - 1:01pm

It allows the direct measurement of gene expression and genetic alteration at scale with single cell resolution to quantify intracellular heterogeneity and characterize cell types, states, and cellular transition dynamics.

Key Points: 
  • It allows the direct measurement of gene expression and genetic alteration at scale with single cell resolution to quantify intracellular heterogeneity and characterize cell types, states, and cellular transition dynamics.
  • The service includes support for Single Cell Gene Expression, Single Cell Immune Profiling, Single Nucleus Gene Expression, Single Cell Multiome ATAC, and Spatial Gene Expression (Visium).\n\xe2\x80\x9cWe are thrilled to support Geninus in providing a world-class Single Cell Analysis experience for their customers while simultaneously enabling real-time collaboration within an advanced multi-omic discovery platform,\xe2\x80\x9d said Tim Wesselman, CEO of ROSALIND.
  • Geninus currently offers the tumor genome profiling platform CancerSCAN\xc2\xae, liquid biopsy-based LiquidSCAN\xc2\xae, and single cell RNA sequencing-based Celinus\xe2\x84\xa2 for serving the needs of clinicians, academic researchers, and pharmaceutical companies.
  • Until now, bioinformatic analysis has been one of the biggest bottlenecks of fully understanding and completing single cell research projects.